STORY – The laboratory boosts its R&D and multiplies acquisitions. Its non-Covid sales will double by 2030.
That was four years ago almost to the day. Albert Bourla was speaking in San Francisco at the JPMorgan Conference, the annual high mass of the pharmaceutical sector. His first intervention as CEO of Pfizer, this veteran of the house having taken charge a week earlier. At the time, the American laboratory came out of a desert crossing linked to the expiration of the patents of several of its star drugs, including Viagra or Lipitor (anticholesterol). Bourla is optimistic, convinced that a new era is dawning for the New York laboratory.
At the beginning of 2020, before the wave of the Covid, he is back in San Francisco but he is struggling to convince his peers that his portfolio of drugs in development will allow him to make a new start. He regrets that Pfizer is underestimated by analysts.
Three years later, the Greek Albert Bourla is welcomed as a star, crowned with his success in the race for vaccines against Covid. His…
This article is for subscribers only. You have 84% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login